Fubotv earnings beat by $0.10, revenue topped estimates
Emily M. Leproust, Chief Executive Officer of Twist Bioscience Corp (NASDAQ:TWST), sold 5,585 shares of common stock on August 4, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The transaction comes as the stock has experienced significant volatility, declining over 20% in the past week and trading near its 52-week low of $27.12.
The shares were sold at a price of $28.364, for a total transaction value of $158,412. Following the transaction, Leproust directly owns 639,721 shares of Twist Bioscience Corp, representing a stake in the $1.56 billion market cap company. InvestingPro analysis shows the company maintains a FAIR financial health score, with 10+ additional insights available to subscribers through comprehensive Pro Research Reports.
In other recent news, Twist Bioscience reported an 18% year-over-year increase in revenue for Q3 2025, reaching $96.1 million. Despite the revenue growth, the company experienced an adjusted EBITDA loss of $8 million, which marks an improvement compared to the previous fiscal year. Twist Bioscience also announced the appointment of Trynka Shineman Blake to its board of directors, where she will serve on the audit committee. Shineman Blake brings extensive leadership experience from her previous role as CEO of Vistaprint.
In terms of analyst evaluations, JPMorgan lowered its price target for Twist Bioscience from $33 to $25 while maintaining an Underweight rating. TD Cowen also reduced its price target from $58 to $36, keeping a Buy rating, citing adjustments in the company’s fiscal year 2025 guidance. Meanwhile, Evercore ISI decreased its price target from $50 to $46, maintaining an Outperform rating, following strong performance in the next-generation sequencing segment. These developments reflect the evolving financial landscape and strategic decisions at Twist Bioscience.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.